2025-04-27 - Analysis Report
## Natera Inc. (NTRA) Stock Review

**0. Key Figures Summary:**

* **Cumulative Return (NTRA):** 133.46%
* **Cumulative Return (VOO):** 78.33%
* **Return Difference (NTRA vs VOO):** 55.1%
* **Relative Divergence:** 15.4% (Indicates NTRA's performance is above the 15.4th percentile of its historical divergence from VOO)
* **Current Price:** $153.79


**1. Company Overview and Performance Comparison:**

Natera Inc. is a company that provides genetic testing services.  Over the period analyzed, NTRA significantly outperformed the S&P 500 (VOO), exhibiting a cumulative return of 133.46% compared to VOO's 78.33%. This represents a substantial difference of 55.1 percentage points.  The relative divergence of 15.4% suggests that this outperformance is relatively moderate compared to its historical fluctuations against the S&P 500.

**Alpha and Beta Analysis:**

The provided data shows highly volatile alpha and beta values over the years. While some periods show significant alpha (outperformance relative to the market), other periods show negative alpha and substantial negative returns. This indicates high risk and unpredictable performance.  The Beta values fluctuate, suggesting varying levels of market sensitivity over the analyzed periods.  The market capitalization (Cap(B)) has significantly increased over time, indicating growth.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -6.0% | 62.4% | -0.1 | 1.2 |       |
| 2016-2018  | 29.0% | 80.1% | 0.0 | 1.9 |       |
| 2017-2019  | 159.0% | 80.1% | 1.3 | 4.6 |       |
| 2018-2020  | 530.0% | 80.1% | 0.7 | 13.5 |       |
| 2019-2021  | 355.0% | 62.9% | 0.3 | 12.7 |       |
| 2020-2022  | -119.0% | 62.9% | 0.3 | 5.5 |       |
| 2021-2023  | -482.0% | 69.9% | 1.3 | 8.5 |       |
| 2022-2024  | -75.0% | 70.6% | 1.3 | 21.5 |       |
| 2023-2025  | 82.0% | 72.8% | 0.9 | 20.9 |       |


**2. Recent Price Movement:**

* **Current Price:** $153.79
* **Previous Close:** $154.48
* **5-Day Moving Average:** $148.74
* **20-Day Moving Average:** $144.88
* **60-Day Moving Average:** $153.70

The price shows a recent slight downward trend, as the current price is below the 5-day, 20-day, and very slightly below the 60-day moving averages.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.39 (Medium Risk)
* **RSI:** 64.28 (Slightly above neutral; not overbought)
* **PPO:** 0.94 (Positive; suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +0.1 (Short-term upward trend)
* **Expected Return (vs. S&P 500):** 102.3% over the long term (2+ years) – This indicates a significant expected outperformance relative to the S&P 500, but should be viewed with caution due to the volatility previously demonstrated.  The high expected return likely reflects the risk inherent in the investment.  The recent price decrease (-$0.45) does not indicate a major market event (no significant sudden jump or drop).


**4. Recent Earnings Analysis:**

The company has reported negative EPS in recent quarters, indicating losses.  Revenue has been relatively stable, showing slight growth. The repeated -0.95 entry in the table suggests a data entry error or a reporting discrepancy, which requires further investigation.

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-11-12 | -0.26  | $0.44 B      |
| 2024-08-09 | -0.30  | $0.41 B      |
| 2024-05-10 | -0.56  | $0.37 B      |
| 2023-11-09 | -0.95  | $0.27 B      |
| 2024-11-12 | -0.95  | $0.27 B      | *(Possible data error)*


**5. Financial Information:**

Revenue shows a consistent upward trend, while profit margins are also generally increasing, indicating improving efficiency. However, Equity and ROE are negative, which needs further investigation and analysis to understand the underlying causes.  These negative values raise concerns about the company's profitability and financial health.


| Quarter    | Revenue | Profit Margin | Equity  | ROE     |
|------------|----------|---------------|---------|---------|
| 2024-12-31 | $0.48B  | 62.94%        | $1.20B | -4.50%  |
| 2024-09-30 | $0.44B  | 61.79%        | $0.88B | -3.60%  |
| 2024-06-30 | $0.41B  | 58.83%        | $0.84B | -4.48%  |
| 2024-03-31 | $0.37B  | 56.72%        | $0.79B | -8.51%  |
| 2023-12-31 | $0.31B  | 51.38%        | $0.77B | -10.20% |



**6. Overall Analysis:**

NTRA has shown significant historical outperformance against the S&P 500, but this has been accompanied by substantial volatility and periods of considerable losses.  While recent revenue growth is positive, negative EPS and ROE raise serious concerns about the company's profitability and financial health. The high expected return, while enticing, must be considered in light of the high risk profile.  Further investigation is needed to clarify the inconsistencies in the provided data (repeated earnings data point and negative ROE despite positive profit margin).  A thorough due diligence process, including analysis of the company’s underlying business model and competitive landscape, is crucial before any investment decision.  The high volatility makes this a potentially high-risk, high-reward investment, not suitable for all investors.
